AVHHL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 19:43):

Stats
Šios dienos apimtis	100.00
Vidutinė apimtis	93.00
Rinkos kapitalizacija	223.17M
EPS	$-34.30 ( 2023-09-29 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.46
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Shiroma Donna	Buy	100 000	Stock Options (Right to Buy)
2023-11-30	Shiroma Donna	Buy	1 469	Common Stock
2024-01-03	O'toole David D	Buy	125 000	Stock Options (Right to Buy)
2023-12-26	Corbett James	Sell	1 445	Common
2023-12-21	Cook Jeremy Curnock	Sell	2 500	Common

INSIDER POWER
67.81
Last 51 transactions
Buy: 875 519 \| Sell: 317 706

AVITA Medical, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

AVITA Medical, Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$34.42M
Bruto pelnas:	$28.38M (82.45 %)
EPS:	$-0.240

FY	2022
Pajamos:	$34.42M
Bruto pelnas:	$28.38M (82.45 %)
EPS:	$-0.240

FY	2021
Pajamos:	$29.23M
Bruto pelnas:	$23.28M (79.65 %)
EPS:	$-0.234

FY	2020
Pajamos:	$14.26M
Bruto pelnas:	$11.29M (79.16 %)
EPS:	$-0.414

Financial Reports:

No articles found.

AVITA Medical, Inc.

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.